Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

6.29
-0.5450-7.97%
Post-market: 6.380.0900+1.43%19:59 EDT
Volume:8.36M
Turnover:53.59M
Market Cap:365.69M
PE:-2.55
High:7.08
Open:6.81
Low:6.01
Close:6.84
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.38
T/O Rate:18.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:1.49
PE(LYR):-2.78

Loading ...

B. Riley Securities Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Jul 27

Capricor Therapeutics Shares Fall 68% After US FDA Flags Concerns over Its Duchenne Therapy

THOMSON REUTERS
·
Jul 27

FDA Staff Flags Concerns for Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 27

Capricor Therapeutics Shares Fall 60% Premarket After FDA Staff Review Says Data for Co's Duchenne Cell Therapy Does not Provide Substantial Evidence of Effectiveness

THOMSON REUTERS
·
Jul 27

Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel

Simply Wall St.
·
Jul 27

Longeveron Elects Deborah Ascheim to Board of Directors

Reuters
·
Jul 23

Capricor Therapeutics Signs Strategic Headquarters Lease Agreement

TIPRANKS
·
Jul 15

Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus

Simply Wall St.
·
Jul 05

Capricor CFO Anthony Bergmann Disposes of USD 732,158 in Common Shares

Reuters
·
Jun 30

Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy

MT Newswires Live
·
Jun 29

Capricor Therapeutics (CAPR) Is Down 6.8% After Positive Five-Year HOPE-2 DMD Data And FDA Update

Simply Wall St.
·
Jun 28

What's Going On With Capricor Therapeutics Stock On Friday?

Benzinga
·
Jun 27

Capricor Tumbles as FDA Panel Meet for Duchenne Cell Therapy Adds Risk Worries

Reuters
·
Jun 26

Capricor Therapeutics to Face FDA Advisory Panel Review of Deramiocel BLA in Duchenne Muscular Dystrophy

Reuters
·
Jun 26

Capricor announces FDA advisory committee meeting to review Deramiocel BLA

TIPRANKS
·
Jun 26

Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set for August 22

Reuters
·
Jun 26

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review Bla for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jun 26

Capricor Therapeutics - Deramiocel Bla Pdufa Target Action Date Set for August 22, 2026

THOMSON REUTERS
·
Jun 26

Capricor presents five-year data from HOPE-2 open-label extension study

TIPRANKS
·
Jun 26

Capricor Says Deramiocel Meets Primary Endpoint in Hope-3 Phase 3 Duchenne Muscular Dystrophy Trial

Reuters
·
Jun 26